MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway
Scientists make cancer breakthrough that could improve immunotherapy success rate
10 November 2022Healthy plant-based diets better for the environment than less healthy plant-based diets
10 November 2022MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway
A new research paper titled “MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway” has been published in Oncotarget.
